Literature DB >> 3965120

Generation of clonal variants in a human ovarian carcinoma studied by chromosome banding analysis.

J M Trent, F H Thompson, R N Buick.   

Abstract

We have utilized detailed chromosome banding analysis to document the selection of variant genetic clones existing in cell populations obtained from a patient with ovarian adenocarcinoma. Cytogenetic analysis was performed on two samples from the patient's malignant ascites obtained over a 9-month interval. Tumor cell lines were also established in monolayer culture from each ascites sample, analyzed by chromosome banding techniques, and compared to the clonogenic population grown from each ascites specimen. Appearance of karyotypically distinct populations were identified from both the in vivo tumor and the tumor cell lines. Tumor colony-forming units (TCFU) evidenced minimal karyotypic change between the original ascites tumor and the ascites sample obtained after a 9-month period in vivo. In contrast, the cell lines derived from these two ascites samples demonstrated markedly different karyotypic populations between samples and progressive chromosome change within each sample following prolonged in vitro growth.

Entities:  

Mesh:

Year:  1985        PMID: 3965120     DOI: 10.1016/0165-4608(85)90226-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

Review 1.  Cytogenetic and molecular biologic alterations in human breast cancer: a review.

Authors:  J M Trent
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

2.  Epidermal growth factor receptor overexpression and trisomy 7 in a case of Barrett's esophagus.

Authors:  H Garewal; P Meltzer; J Trent; R Prabhala; R Sampliner; M Korc
Journal:  Dig Dis Sci       Date:  1990-09       Impact factor: 3.199

3.  Involvement of chromosome 6 in endometrial cancer.

Authors:  M G Tibiletti; B Bernasconi; M Taborelli; D Furlan; A Fabbri; M Franchi; R Taramelli; M Trubia; C Capella
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.